Activ-Film technology developed by AptarGroup Inc. has been selected to protect a new rapid SARS antigen test for COVID-19 that recently received emergency use clearance from FDA. Aptar designs and manufactures a range of solutions for the delivery of drugs, consumables and active materials.
The SARS QuickVue Point-of-Care Antigen Test was developed by Quidel Corp., a manufacturer of diagnostic health products. The visual reading test provides results in 10 minutes and requires no additional instrumentation. It offers extended access to affordable and accurate COVID-19 testing that will help meet the urgent testing needs of the global economy, including in school systems and rural areas, Quidel said.
Activ-Film from Aptar CSP Technologies is integrated into the diagnostic kit to protect against moisture and other environmental conditions that could affect the accuracy of the test. Activ-Film leverages Aptar’s patented 3-phase Activ-Polymer technology, which provides a broad spectrum of customized protection in a variety of configurations, such as Activ-Vial for housing diagnostic sticks and …
Read More On Original Publisher
This Content is Original Published by @www.plasticstoday.com